OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
NEW YORK, March 08, 2017 -- Shepherd, Finkelman, Miller & Shah, LLP (“SFMS”) announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York (Civil Action No. 17-01233) against Alcobra, Ltd. (“Alcobra”)(Nasdaq:ADHD) and certain of its officers and directors. The case seeks remedies under the Securities Exchange Act of 1934 and is brought on behalf of a class consisting of all persons or entities who acquired Alcobra securities between August 13, 2015 and January 17, 2017, inclusive (the “Class Period”).
Alcobra is a biopharmaceutical company that focuses on the development and commercialization of oral drug candidates. Alcobra’s primary drug candidate in development, metadoxine extended release (“MDX”), is in its second Phase III clinical trial for adults with ADHD.
The Complaint alleges that, throughout the Class Period, Alcobra made false and/or misleading statements and/or failed to disclose that: (1) the results of Alcobra’s first Phase III study in October 2014 revealed no statistically significant benefit derived from MDX; (2) given that the composition of MDX was unaltered from the first Phase III study, there was no basis to expect results of the second trial to be any different; (3) removing extreme placebo response patients from the analysis of the second Phase III trial did not boost the MDX trial results as Alcobra anticipated; and (4) Alcobra attributed all improvements in subjects taking MDX in the second Phase III trial to the effects of the drug, while disregarding any spontaneous improvements by placebo patients.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. If you purchased or otherwise acquired Alcobra securities during the Class Period, we encourage you to contact us with any questions prior to the April 18, 2017 lead plaintiff motion deadline.
SFMS is recognized as an accomplished firm in the areas of securities, corporate governance, antitrust and employee benefits litigation with offices in California, Connecticut, Florida, New Jersey, New York and Pennsylvania. For more information visit us at http://www.sfmslaw.com.
Contact: Bruce Parke, [email protected] Shepherd Finkelman Miller & Shah, LLP Telephone: (866) 540-5504
